Efficient tumor targeting by single-domain antibody fragments of camels

被引:230
作者
Cortez-Retamozo, V [1 ]
Lauwereys, M [1 ]
Gh, GH [1 ]
Gobert, M [1 ]
Conrath, K [1 ]
Muyldermans, S [1 ]
De Baetselier, P [1 ]
Revets, H [1 ]
机构
[1] Free Univ Brussels VIB, Dept Cellular Immunol, B-1640 Rhode St Genese, Belgium
关键词
camel antibodies; single-domain antibodies; tumor targeting; affinity; lysozyme;
D O I
10.1002/ijc.10212
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The variable domain of functional heavy chain antibodies (VHH) devoid of light chains, found in camels, constitute the smallest intact antigen-binding domain fragment. Two camel single-domain fragments, cAb-Lys2 and cAb-Lys3, recognizing an overlapping epitope of lysozyme with a dissociation constant of 2 nM and 6S nM, respectively, and a bivalent cAb-Lys3 were investigated for their ability to target transgenic tumors expressing lysozyme on their membrane. Biodistribution studies revealed that these non-immunogenic monomeric and bivalent camel single-domain antigen binders specifically target lysozyme-expressing tumors and metastatic lesions. The excess of antibody is rapidly eliminated from the blood circulation and no cAb retention was observed in normal organs. The tumor to organ cAb-ratios at 2 and 8 hr were in the (2.1-10.8):1 and (6.2-23.7):1 range, respectively. The degree and specificity of tumor retention is independent of the affinity of the recombinant camel single-domain fragments for their antigen and from their univalent monomeric (15 kDa) or bivalent format (33 kDa). This study demonstrates the successful and specific in vivo targeting of tumors by camel single-domain fragments. It may open perspectives for their future use as tumor-targeting vehicle, due to their small size, soluble behaviour and because they are non-immunogenic and interact with epitopes that are less antigenic for conventional antibodies. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:456 / 462
页数:7
相关论文
共 36 条
  • [1] Adams GP, 2001, CANCER RES, V61, P4750
  • [2] Adams GP, 1998, CANCER RES, V58, P485
  • [3] Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu
    Adams, GP
    Schier, R
    McCall, AM
    Crawford, RS
    Wolf, EJ
    Weiner, LM
    Marks, JD
    [J]. BRITISH JOURNAL OF CANCER, 1998, 77 (09) : 1405 - 1412
  • [4] SINGLE-CHAIN ANTIGEN-BINDING PROTEINS
    BIRD, RE
    HARDMAN, KD
    JACOBSON, JW
    JOHNSON, S
    KAUFMAN, BM
    LEE, SM
    LEE, T
    POPE, SH
    RIORDAN, GS
    WHITLOW, M
    [J]. SCIENCE, 1988, 242 (4877) : 423 - 426
  • [5] Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs
    Conrath, KE
    Lauwereys, M
    Wyns, L
    Muyldermans, S
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (10) : 7346 - 7350
  • [6] CAMELISING HUMAN-ANTIBODY FRAGMENTS - NMR-STUDIES ON VH DOMAINS
    DAVIES, J
    RIECHMANN, L
    [J]. FEBS LETTERS, 1994, 339 (03) : 285 - 290
  • [7] A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies
    de Haard, HJ
    van Neer, N
    Reurs, A
    Hufton, SE
    Roovers, RC
    Henderikx, P
    de Bruïne, AP
    Arends, JW
    Hoogenboom, HR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (26) : 18218 - 18230
  • [8] ANALYSIS OF ANTIGLOBULIN (HAMA) RESPONSE IN A GROUP OF PATIENTS WITH B-LYMPHOCYTIC MALIGNANCIES TREATED WITH I-131 LYM-1
    DENARDO, GL
    KROGER, LA
    MIRICK, GR
    LAMBORN, KR
    DENARDO, SJ
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1995, 10 (02) : 67 - 74
  • [9] The development of monoclonal antibodies for the therapy of cancer
    Farah, RA
    Clinchy, B
    Herrera, L
    Vitetta, ES
    [J]. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 1998, 8 (3-4): : 321 - 356
  • [10] Isolation of antigen specific Llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae
    Frenken, LGJ
    van der Linden, RHJ
    Hermans, PWJJ
    Bos, JW
    Ruuls, RC
    de Geus, B
    Verrips, CT
    [J]. JOURNAL OF BIOTECHNOLOGY, 2000, 78 (01) : 11 - 21